AZURIN MUTANT WITH MET 121 REPLACED BY GLU

Göran Karlsson(Uppsala University), L. Sjölin, Nicklas Bonander(Chalmers University of Technology), Joann Sanders–Loehr(Chalmers University of Technology), L.‐C. Tsai(Chalmers University of Technology), Herbert Nar(Boehringer Ingelheim (Germany)), Vratislav Langer(Chalmers University of Technology)

Unknown

January 11, 1997

10.2210/pdb1etj/pdb

Cited by 0

Related Papers

A specific antidote for dabigatran: functional and structural characterization

|Blood|2013|562

Crystal structure analysis of oxidized Pseudomonas aeruginosa azurin at pH 5·5 and pH 9·0

|Journal of Molecular Biology|1991|487

Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors

|Journal of Medicinal Chemistry|2002|454

Biophysics in drug discovery: impact, challenges and opportunities

|Nature Reviews Drug Discovery|2016|383

8-(3-(<i>R</i>)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

|Journal of Medicinal Chemistry|2007|285